Teva’s Phase IIb chronic migraine trial of TEV-48125 meets primary and secondary endpoints
The trial evaluated the efficacy, safety, tolerability as well as compared two active arms of different doses of TEV-48125, administered as a subcutaneous injection, once a month for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.